# Filing Detail

Form PREM14A - Preliminary proxy statements relating to merger or acquisition:
SEC Accession No. 0001140361-22-010241
Filing Date
2022-03-18
Accepted
2022-03-18 17:24:27
Documents
9
Period of Report
2022-03-18

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | PREM14A | ny20003153x3_prem14a.htm | PREM14A | 5309621
2 | FILING FEES TABLE | ny20003153x3_ex107.htm | EX-FILING FEES | 32650
3 |  | logo_centerviewpartnersv2.jpg | GRAPHIC | 20936
4 |  | logo_neogen.jpg | GRAPHIC | 30841
5 |  | ny20003153x3_flowchart0x1.jpg | GRAPHIC | 70366
6 |  | ny20003153x3_flowchart0x2.jpg | GRAPHIC | 108364
7 |  | ny20003153x3_flowchart0x3.jpg | GRAPHIC | 111789
8 |  | ny20003153x3_piechart01.jpg | GRAPHIC | 64155
9 |  | ny20003153x3_piechart02.jpg | GRAPHIC | 47573
| Complete submission text file | 0001140361-22-010241.txt |  | 5967411

Mailing Address 620 LESHER PLACE LANSING MI 48912
Business Address 620 LESHER PLACE LANSING MI 48912 5173729200
NEOGEN CORP (Filer) CIK: 0000711377 (see all company filings)

EIN.: 382367843 | State of Incorp.: MI | Fiscal Year End: 0531
Type: PREM14A | Act: 34 | File No.: 000-17988 | Film No.: 22753529
SIC: 2835 In Vitro & In Vivo Diagnostic Substances